Description: Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106; and Evotec AG for the novel target for fibrosis and other indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Home Page: www.glpg.com
Generaal De Wittelaan L11 A3
Mechelen,
2800
Belgium
Phone:
32 1 534 29 00
Officers
| Name | Title |
|---|---|
| Mr. Bart Filius M.B.A., MBA | Pres, COO & Member of Management Board |
| Dr. Andre Hoekema Ph.D. | Chief Bus. Officer & Member of Management Board |
| Dr. Walid Abi-Saab | Chief Medical Officer & Member of Management Board |
| Mr. Michele Manto M.B.A. | Chief Commercial Officer & Member of Management Board |
| Dr. Paulus A. Stoffels M.D., Ph.D. | CEO, Chairman & Member of Management Board |
| Ms. Elizabeth Goodwin | VP of Investor Relations |
| Ms. Sofie Van Gijsel | Head of Investor Relations |
| Marieke Vermeersch | Head of Corp. Communication |
| John Montana | Managing Director of Argenta |
| Ms. Chantal Tasset | Head of Devel. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 78.7402 |
|---|---|
| Trailing PE: | 433 |
| Price-to-Book MRQ: | 0.9156 |
| Price-to-Sales TTM: | 4.5058 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1357 |